Romania · Delayed Price · Currency is RON Teraplast Earnings Call Transcripts
Fiscal Year 2025
-
Turnover grew 21% to RON 1.08 billion in 2025, with EBITDA up 75% and net profit reversing prior losses. Strong international sales and M&A integration drove results, while 2026 targets further growth and improved margins.
-
Turnover rose 26% to RON 857 million and EBITDA grew 59% to RON 72 million, driven by volume growth and M&A. Net profit reached RON 6.3 million, reversing last year's loss, with strong export gains and improved margins despite higher raw material and financial costs.
-
Consolidated sales rose 29% year-over-year to RON 552 million, with EBITDA up 74% and net profit reversing last year's loss, driven by acquisitions and strong infrastructure demand. Packaging remains challenging, but leverage is expected to improve by year-end.
Fiscal Year 2024
-
Revenue grew 33.5% in 2024, driven by acquisitions and volume growth, but margin pressure led to a net loss. 2025 guidance targets 12% revenue growth, a 69% EBITDA increase, and a return to profitability, with a focus on consolidating recent acquisitions and operational improvements.
-
Turnover rose over 30% year-over-year, driven by acquisitions and volume growth, but EBITDA margins declined and the group posted a net loss due to cost pressures and underperforming segments. Expansion continues with the Optiplast acquisition pending, while cautious optimism is held for 2025.
-
Turnover grew 34% year-over-year in H1 2024, driven by infrastructure demand, M&A, and export expansion. EBITDA rose 15%, but margin declined due to aggressive pricing and integration costs. Net loss resulted from non-recurring items, with positive outlook for H2.